Sprint Bioscience

15/06/2026

The Sprint Bioscience team with CBO Anne-Marie Wenthzel-Buckhöj and CSO Martin Andersson, is gearing up for in San Diego next week.
As the world’s largest biotech gathering, BIO International Convention by Biotechnology Innovation Organization unites our industry to shape the future of healthcare. It’s where innovation meets opportunity, and we’re looking forward to connecting. Our meeting schedule is nearly full, but there’s still an opportunity to connect, reach out via the partnering system to secure a conversation ➡️🔐 https://partner.bio.org/

Sweden will be strongly represented, with a dynamic delegation spanning biotech, pharma, medtech, and life science services. At the Swedish Pavilion, you’ll experience the breadth of Sweden’s life science ecosystem (and cinnamonbuns), from established global companies to pioneering startups, demonstrating how Swedish innovation is driving the next wave of healthcare solutions through new technologies and partnerships. Let’s explore new possibilities in oncology and drug development together.
📍 Visit the Swedish Pavilion ( #3417), next to the registration area and the Digital Health & AI Zone.

11/06/2026

On a bright (pun intended!) and sunny day in May, Sprint Bioscience had the pleasure of visiting MAX IV Laboratory in Lund, a place that truly feels like an extension of our labs in Flemingsberg. In this article by BioStock - Connecting Innovation & Capital🔗https://biostock.se/en/2026/06/sprint-bioscience-forskar-med-en-av-varldens-ljusstarkaste-rontgenkallor/ you can read more about it.

For Sprint Bioscience, MAX IV plays a central role in our ability to push the boundaries of structure-based drug discovery. Access to a world-leading synchrotron light source, with its exceptional brightness and precision, enables us to generate high-quality structural data that directly accelerates our drug development programs. But beyond the technology itself, the collaboration has strengthened how we work.
By combining structural biology with fragment-based approaches, we can explore multiple chemical tracks in parallel and rapidly identify molecules with promising drug-like properties. This way of working remains relatively rare, not only in Sweden but globally, and gives us a strong strategic advantage.
Rather than relying on traditional high-throughput screening (HTS), we are built on the principle of “designing right from the start.” Structural insights allow us to understand how molecules interact with their target proteins at the atomic level, guiding every iteration in our process. Between each cycle, crystallography helps us confirm: are we on the right path, and are we optimizing in the best possible way? This results in higher-quality programs. When we know exactly how a molecule binds to its target, we can intelligently refine and optimize it. The outcome is not just a single molecule, but a comprehensive package, including lead series, backup series, and valuable intellectual property, that significantly strengthens the value for our partners.
We are proud to collaborate with MAX IV as part of a uniquely strong Swedish innovation ecosystem, where cutting-edge infrastructure, science, and industry come together to drive the next generation of therapies. Our structural biologists and proteincrystallographers Lionel Trésaugues and Wimal Ubhayasekera lead our way forward.

Thanks to MAX IV’s Industrial Relations Office team for an insightful and engaging visit!

10/06/2026

Sprint Bioscience CEO Johan Emilsson presented the company at Aktiedagarna Stockholm, an investor event hosted by Aktiespararna on June 9. During the session, he provided an overview of our operations, strategy, and pipeline, followed by a Q&A discussion.

The full presentation and subsequent Q&A session is available here🎥 https://sprintbioscience.com/sv/film/aktiedagarna-stockholm-2026/

04/06/2026

Sprint Bioscience has commissioned Aktiespararna (the Swedish Shareholders’ Association) and its research service, Analysguiden, to publish an initiation report focused on our operations, business model, and pipeline.
The report is now available: https://www.aktiespararna.se/analyser/sprint-bioscience-innovation-och-affar
In addition to this CEO Johan Emilsson will present the company at Aktiedagarna in Stockholm on June 9 at 16:00 CEST. More information about the event can be found here: 🔗https://www.aktiespararna.se/aktiviteter/aktiedagarna-i-stockholm-68173
The event will be live-streamed and no registration is required:
🎥https://invitepeople.com/public/events/fa647c6285/pages/ea19175b1c

Please note that the main language of the event is Swedish.

Sprint Bioscience intar en speciell roll inom svensk läkemedelsutveckling. Bolaget har en relativt omfattande preklinisk portfölj av olika program inom innovativ cancerforskning och vi räknar med att dessa program ska tillåta bolaget att fortsätta göra licensaffärer. Förra årets affär med ...

28/05/2026

Tune in to hear Sprint Bioscience featured on the Market Makers podcast🎙️CEO Johan Emilsson joins for an interview.

Market Makers is one of Sweden’s largest finance podcasts, focusing on investments in growth and technology stocks. Since its launch in 2017, the podcast has accumulated over 4 million listens and built a loyal audience. New episodes are released every Thursday, featuring stock cases, market insights, and analysis across sectors.

In the latest episode, Johan talks about what we do at Sprint Bioscience and, most importantly, how we do it, while also answering questions about our business and strategy.

📻 Listen to the episode here (available in Swedish): https://shows.acast.com/marketmakers/episodes/434-kina-och-norgerisken

25/05/2026

Now available: watch the recordings from Global Forum 2026, including Sprint Bioscience CEO Johan Emilsson presenting the company:
🎥 https://biostock.se/2026/05/sprint-bioscience-global-forum-2026/
The event gathered a strong international audience of investors, BD&L representatives, and industry experts. Through several engaging and insightful panel discussions, key topics such as global market expansion, strategic partnerships, and access to international capital were explored.

A big thank you to the organizers BioStock - Connecting Innovation & Capital for a well-executed and rewarding event.

Foto by: Johan Bävman

15/05/2026

Sprint Bioscience’s interim report for the first quarter was published this Wednesday.
Johan Emilsson, CEO of Sprint Bioscience, says: “The first quarter of 2026 has been intense and highly productive. We have taken several important steps forward in our programs, broadened the medical and commercial value of our portfolio, and at the same time strengthened the company’s financial and operational foundation.”
The report is also discussed in an interview with Redeye’s analyst Fredrik Thor, which is available here: https://www.redeye.se/research/1166936/sprint-bioscience-q1-interview-positive-pipeline-development-and-increased-attention-after-trex1-deal
Download your copy or read online (in Swedish) ▪️ https://sprintbioscience.com/sv/pressmeddelande/?slug=sprint-bioscience-delarsrapport-for-januari-mars-2026

Dont forget to subscribe for future press releases ▪️ https://sprintbioscience.com/en/subscribe/

24/04/2026

Sprint Biosciences CEO Johan Emilsson presented the company and its operations at an investor event hosted by https://www.aktieinfo.net/ Aktieinfo John Stihøj in Aarhus, Denmark, on April 22. We appreciated the opportunity to share insights into our business and to meet members of the investment community, and it was very encouraging to see a strong turnout and high level of engagement from the audience in person. See the presentation and the subsequent Q&A session here 🎞️ https://sprintbioscience.com/en/movie/sprint-bioscience-presenterar-pa-aktieinfo-net-investerartraff/

22/04/2026

Today at AACR 2026 by American Association for Cancer Research (AACR) we are presenting data from our DCPS program, supporting DCPS inhibition as a promising therapeutic strategy for patients with acute myeloid leukemia (AML). The findings go beyond efficacy, providing deeper biological insight into DCPS and highlighting its potential role in improving patient stratification. Sprint Bioscience is represented by CSO Martin Andersson and Associate Principal Scientist Madhurendra Singh. Come by and discuss the data with us!
📍 Biomarkers Predictive of Therapeutic Benefit 6
🗓️ Wednesday, April 22 | Poster Section 41, Board 18

21/04/2026

At a time when the global cancer burden continues to rise, scientific progress cannot afford silos, slowdowns, or hesitation. Breakthroughs happen when knowledge is shared, challenged, and accelerated. That is why Sprint Bioscience is proud to participate in the American Association for Cancer Research (AACR) Annual Meeting 2026, the world’s largest and most influential cancer research convening.

Ahead of the main meeting, our CSO and co‑founder Martin Andersson participated in the AACR Oncology Industry Partnering Event (April 16–17), engaging with leaders across biotech and pharma. These discussions are where science meets strategy and where discoveries begin their journey toward patients.

The Annual Meeting (April 17–22) is currently underway, where Madhurendra Singh will present new preclinical data from our DCPS program. The poster highlights findings supporting DCPS inhibition as a potential therapeutic strategy for patients with acute myeloid leukemia (AML). Beyond efficacy, the data deepens the biological understanding of DCPS and underscore its potential to improve patient stratification.
🔔Wednesday, April 22 Biomarkers Predictive of Therapeutic Benefit 6 📍Location: Poster Section 41 Poster Board Number: 18

Events like AACR matter because no single lab, company, or discipline can solve cancer alone. In times of scientific complexity, geopolitical uncertainty, and mounting healthcare pressure, platforms for exchange and collaboration are not optional, they are essential.
Cancer does not wait. Neither can drug discovery.